OZOBAX® provides the clinical benefits of baclofen in an oral solution that simplifies titration, enables precise dosing, and provides an easy to swallow medicine for patients with dysphagia.
In MS, oral baclofen demonstrated significantly better efficacy than placebo at improving muscle tone.2
55%-72% of patients experienced an improvement with baclofen compared with the 0%-17.4% of patients who were given placebo.
In open-label studies of oral baclofen, spasticity was improved in 70%-87% of patients who had spasticity of spinal origin.3
Improvement in spasms was reported in 75%-96% of all patients.
Dosing Flexibility and Precision
OZOBAX provides a flexible solution that can be tailored to meet individual patient needs. Initiate OZOBAX with a low dosage, preferably in divided doses, administered orally. The dosage can be increased gradually based on clinical response and tolerability1.
A Solution for Patients with Dysphagia
Data suggest greater than 40% prevalence of dysphagia in patients with MS.4 OZOBAX is an oral solution that may help your patients who have difficulty swallowing baclofen in tablet form.
- OZOBAX [prescribing information]. Athens, GA: Metacel Pharmaceuticals, LLC; 2019.
- ERTZGAARD P, CAMPO C and CALABRESE A. EFFICACY AND SAFETY OF ORAL BACLOFEN IN THE MANAGEMENT OF SPASTICITY: A RATIONALE FOR INTRATHECAL BACLOFEN. J Rehabil Med 2017; 49: 193–203.
- Dario, A., Tomei, G. A Benefit-Risk Assessment of Baclofen in Severe Spinal Spasticity. Drug-Safety 27, 799–818 (2004) doi:10.2165/00002018-200427110-00004
- Aghaz A, Alidad A, Hemmati E, Jadidi H, Ghelichi L. Prevalence of dysphagia in multiple sclerosis and its related factors: systematic review and meta-analysis. Iran J Neurol. 2018;17(4):180–188.